JP2022547335A5 - - Google Patents
Info
- Publication number
- JP2022547335A5 JP2022547335A5 JP2022516691A JP2022516691A JP2022547335A5 JP 2022547335 A5 JP2022547335 A5 JP 2022547335A5 JP 2022516691 A JP2022516691 A JP 2022516691A JP 2022516691 A JP2022516691 A JP 2022516691A JP 2022547335 A5 JP2022547335 A5 JP 2022547335A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg
- amino acid
- acid sequence
- fusion polypeptide
- egf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025136792A JP2025186253A (ja) | 2019-09-16 | 2025-08-20 | 組換えヒトニューレグリン誘導体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910873003 | 2019-09-16 | ||
| CN201910873003.9 | 2019-09-16 | ||
| CN202010955006.X | 2020-09-11 | ||
| CN202010955006.XA CN112500493A (zh) | 2019-09-16 | 2020-09-11 | 重组人神经调节蛋白衍生物及其用途 |
| PCT/CN2020/114955 WO2021052277A1 (zh) | 2019-09-16 | 2020-09-14 | 重组人神经调节蛋白衍生物及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136792A Division JP2025186253A (ja) | 2019-09-16 | 2025-08-20 | 組換えヒトニューレグリン誘導体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547335A JP2022547335A (ja) | 2022-11-11 |
| JP2022547335A5 true JP2022547335A5 (enExample) | 2023-09-15 |
Family
ID=74883174
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516691A Pending JP2022547335A (ja) | 2019-09-16 | 2020-09-14 | 組換えヒトニューレグリン誘導体及びその使用 |
| JP2025136792A Pending JP2025186253A (ja) | 2019-09-16 | 2025-08-20 | 組換えヒトニューレグリン誘導体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136792A Pending JP2025186253A (ja) | 2019-09-16 | 2025-08-20 | 組換えヒトニューレグリン誘導体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230057622A1 (enExample) |
| EP (1) | EP4032901A4 (enExample) |
| JP (2) | JP2022547335A (enExample) |
| KR (1) | KR20220066116A (enExample) |
| AU (1) | AU2020348436A1 (enExample) |
| CA (1) | CA3157354A1 (enExample) |
| WO (1) | WO2021052277A1 (enExample) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| AU745324B2 (en) | 1997-10-14 | 2002-03-21 | Cenes Pharmaceuticals, Inc. | Therapeutic methods comprising use of a neuregulin |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| US20110166068A1 (en) * | 2008-07-17 | 2011-07-07 | Acorda Therapeutics, Inc. | Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure |
| WO2013053076A1 (en) * | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| GB201313235D0 (en) * | 2013-07-24 | 2013-09-04 | Univ Edinburgh | Antiviral Compositions Methods and Animals |
| CN110946993A (zh) * | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) * | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| JP2020514370A (ja) * | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤 |
| CN108623672A (zh) * | 2017-03-25 | 2018-10-09 | 成都贝爱特生物科技有限公司 | 新的egf-a和b的组合突变体制备及其在生物药物中的应用 |
| AU2019209770B2 (en) * | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| FI3774859T3 (fi) * | 2018-04-11 | 2024-05-24 | Salubris Biotherapeutics Inc | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät |
-
2020
- 2020-09-14 JP JP2022516691A patent/JP2022547335A/ja active Pending
- 2020-09-14 US US17/642,855 patent/US20230057622A1/en active Pending
- 2020-09-14 EP EP20865911.0A patent/EP4032901A4/en active Pending
- 2020-09-14 AU AU2020348436A patent/AU2020348436A1/en active Pending
- 2020-09-14 KR KR1020227012793A patent/KR20220066116A/ko active Pending
- 2020-09-14 WO PCT/CN2020/114955 patent/WO2021052277A1/zh not_active Ceased
- 2020-09-14 CA CA3157354A patent/CA3157354A1/en active Pending
-
2025
- 2025-08-20 JP JP2025136792A patent/JP2025186253A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220403009A1 (en) | Multimeric coronavirus binding molecules and uses thereof | |
| JP2010522540A5 (enExample) | ||
| JP2018515088A5 (enExample) | ||
| TWI648401B (zh) | 生長分化因子１５（ｇｄｆ－１５）構築體 | |
| JP5823954B2 (ja) | Ｆｇｆ２１変異体及びその使用 | |
| CN102292346B (zh) | 肥胖的治疗 | |
| JP2020169191A5 (enExample) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| JP2015502336A5 (enExample) | ||
| US20230174611A1 (en) | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor | |
| WO1998052415B1 (en) | Substantially pure zonulin, a physiological modulator of mammalian tight junctions | |
| JP2011518179A5 (enExample) | ||
| KR102354845B1 (ko) | 인간화 항 clever-1 항체 및 이의 용도 | |
| CN102917726A (zh) | 干扰素类似物 | |
| CN109734800B (zh) | 一种裂谷热病毒人源单克隆抗体及其应用 | |
| WO2007144198B1 (en) | Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases | |
| US20230242672A1 (en) | Ace2-fc fusion proteins and methods of use | |
| WO2016145385A2 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
| JP2009520758A5 (enExample) | ||
| MX2022008748A (es) | Administración oral de péptidos. | |
| JP2022547335A5 (enExample) | ||
| RU2503684C2 (ru) | Иммуномодулирующие олигопептиды | |
| CA3065552A1 (en) | Hydrochloride salts of c5a receptor agonist peptides | |
| WO2024229151A2 (en) | Multimeric coronavirus binding molecules and uses thereof | |
| EP3267980A1 (en) | Conformationally stable analogs of the response selective c5a agonist ep67 |